Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screening a...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkinson, Sarah, Lubaczewski, Shannon, Ramaker, Sara, England, Richard D., Wajsbrot, Dalia B., Abbas, Richat, Findling, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771531/
https://www.ncbi.nlm.nih.gov/pubmed/29185786
http://dx.doi.org/10.1089/cap.2017.0099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771531/
https://www.ncbi.nlm.nih.gov/pubmed/29185786
http://dx.doi.org/10.1089/cap.2017.0099

Ejemplares similares